Compile Data Set for Download or QSAR
Report error Found 326 Enz. Inhib. hit(s) with Target = 'Receptor-interacting serine/threonine-protein kinase 1 [8-327]'
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530010((3R)-4-[4-fluoro-1- (5-fluoropyrimidin- 2-yl)piper...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530014(4-[2-[1-(5- fluoropyrimidin-2- yl)pyrrolidin-3-yl]...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530013(4-(cis-3-(5- fluoropyrimidin-2- yl)-3- azabicyclo[...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530020(4-[3,3-difluoro-1- (5-fluoropyrimidin- 2-yl)-4-met...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530021(4-(4-fluoro-1- quinazolin-2-yl- piperidine-4- carb...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529993(4-[2-methyl-2- (trifluoromethoxy) propanoyl]-3,5- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530226(US11203600, Example 308 | Preparation of 4-[(4R)-3...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529998(4-[2-(cyanomethyl)- 2-methyl-butanoyl]- 3,5-dihydr...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529999((3R)-4-(2,2- dimethylbutanoyl)- 3-methyl-3,5- dihy...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530002((3R)-4-(2,2- dimethylpropanoyl)- 3-methyl-3,5- dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530001((3R)-4-(3-fluoro- 2,2-dimethyl- propanoyl)-3- meth...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530008(4-[2-(3,3- difluorocyclobutyl)- 2-methyl- propanoy...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530042(4-[1-(5-fluoro-4- methoxy-pyrimidin- 2-yl)piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530041(4-[1-(4- methoxypyrimidin- 2-yl)piperidine-4- carb...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530044((3R)-4-(1-(5- fluoro-4- methoxypyrimidin- 2-yl)pip...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530043((3R)-4-(1-(4- methoxypyrimidin- 2-yl)piperidine-4-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530046((9-fluoro-3,5- dihydro-2H- pyrido[3,4- f][1,4]oxaz...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530045((9-fluoro-3,5- dihydro-2H- pyrido[3,4- f][1,4]oxaz...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530048(4-[1-[4- (cyclopropylamino)- 5-fluoro- pyrimidin-2...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530050(4-[4-fluoro-1-(5- fluoro-4- methylsulfanyl- pyrimi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530049(4-[1-[4-(2,2- difluoroethoxy)-5- fluoro-pyrimidin-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530052(4-[1-(5-chloro-4- methoxy-pyrimidin- 2-yl)-4-fluor...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530054((9-fluoro-3,5- dihydro-2H- pyrido[3,4- f][1,4]oxaz...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530053(4-[1-(5-chloro-4- methoxy-pyrimidin- 2-yl)piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530056((1-(4-(2,2- difluoroethoxy)-5- fluoropyrimidin-2- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530055(4-(1-(4-(2,2- difluoroethoxy)-5- fluoropyrimidin-2...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530028((3R)-4-(1-(5- fluoropyrimidin-2- yl)piperidine-4- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530027(4-[4-fluoro-1-(4- methoxypyrimidin- 2-yl)piperidin...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530029((3R)-4-[1-(5- fluoropyrimidin-2- yl)-4-methoxy- pi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530034(4-(4-fluoro-1- (pyrazolo[1,5- a]pyrimidin-7- yl)pi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530038(4-[4-fluoro-1-(5- fluoro-2-methoxy- pyrimidin-4- y...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530075(4-(2-ethyl-2- methyl-butanoyl)- 3,5-dihydro-2H- py...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530077(4-(2-methoxy-2- methyl-butanoyl)- 3,5-dihydro-2H- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530080((9-fluoro-3,5- dihydro-2H- pyrido[3,4- f][1,4]oxaz...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530079(4-[1-(5- fluoropyrimidin-2- yl)piperidine-4- carbo...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530082(4-(2-chloro-2- methyl-propanoyl)- 3,5-dihydro-2H- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530081(4-(4-fluoro-1- pyrimidin-2-yl- piperidine-4- carbo...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530085(4-[4-fluoro-1-(5- fluoropyrimidin-2- yl)piperidine...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530088(4-[1-(5- chloropyrimidin-2- yl)-4-fluoro- piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530059((9-fluoro-3,5- dihydro-2H- pyrido[3,4- f][1,4]oxaz...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530066(4-(3,3-difluoro-2,2- dimethyl-butanoyl)- 3,5-dihyd...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530068(4-(3-fluoro-2,2- dimethyl- propanoyl)-3,5- dihydro...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530069(4-(2,2,3- trimethylbutanoyl)- 3,5-dihydro-2H- pyri...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530072(4-(2-methyl-2- methylsulfanyl- propanoyl)-3,5- dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530071(4-[3-fluoro-2- (fluoromethyl)-2- methyl-propanoyl]...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530106(4-[1-(5- fluoropyrimidin-2- yl)piperidine-4- carbo...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530108(4-[1-(5- fluoropyrimidin-2- yl)-4-methoxy- piperid...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530107(4-[4-fluoro-1-(5- fluoro-4-methyl- pyrimidin-2- yl...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530110(4-[1-(5- fluoropyrimidin-2- yl)-3-methyl- piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530111(4-[4-fluoro-1-(5- fluoro-2- pyridyl)piperidine- 4-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2022
Entry Details
US Patent

Displayed 1 to 50 (of 326 total ) | Next | Last >>
Jump to: